PALO ALTO, Calif.--Michael Steinmetz, managing director of the biotechnology venture capital firm Venture Asset Management, Cambridge, Mass., was elected to the board of directors of the bioinformation technology company Caliper Technologies here. Steinmetz also serves as acting CEO of the new, Munich-based, functional genomics company Genome Pharmaceuticals, and was previously vice-president of preclinical R&D for Hoffmann-LaRoche.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
You may already have institutional access!
Check if I qualify.
Already a GenomeWeb or 360Dx Premium member?
Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.